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Abstract Prion diseases are characterized by the accu-
mulation of diffuse and aggregated plaques of protease-
resistant prion protein (PrP) in the brains of affected
individuals and animals. Whereas prion diseases in ani-
mals appear to be almost exclusively transmitted by
infection, human prion diseases most often occur spo-
radically and, to a lesser extent, by inheritance or
infection. In the sporadic cases (sporadic Creutzfeld-
Jakob disease, sCJD), PrP-containing plaques are
infrequent, whereas in transmitted (variant CJD) and
inherited (Gerstmann-Straussler-Scheinker Syndrome)
cases, plaques are a usual feature. In the current study,
representative cases from each of the classes of human
prion disease were analyzed for the presence of markers
of oxidative damage that have been found in other
neurodegenerative diseases. Interestingly, we found that
the pattern of deposition of PrP, amyloid-b, and redox
active metals was distinct for the various prion diseases.
Whereas 8-hydroxyguanosine has been shown to be
increased in sCJD, and inducible NOS is increased in
scrapie-infected mice, well-studied markers of oxidative
damage that accumulate in the lesions of other neuro-
degenerative diseases (such as Alzheimer’s disease, pro-
gressive supranuclear palsy, and Parkinson’s disease),
such as heme oxygenase-1 and lipid peroxidation, were
not found around PrP deposits or in vulnerable neurons.
These findings suggest an important distinction in prion-
related oxidative stress, indicating that different neuro-
degenerative pathways are involved in different prion
diseases.
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Introduction
Prion diseases are associated with a conformational
change in the structure of a normal cellular protein, the
prion protein (PrPC), which results in the production of
a pathogenic protein form that is referred to as PrPSC
[28]. The properties associated with this structural
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change include insolubility in non-ionic detergents,
resistance to digestion with proteases, and the formation
of fibrils after extraction in non-ionic detergents. The
protease resistance of PrPSC has been used extensively in
the diagnosis of prion diseases [21].
Prion diseases affect a variety of organisms ranging
from experimentally infected mice to humans [11, 28].
However, only in humans has the full range of disease
acquisition been demonstrated: sporadic conversion,
inheritance, or infection [9]. When propagated by
infection, prion diseases are usually associated with PrP-
amyloid plaques. Thus, animal diseases such as scrapie,
bovine spongiform encephalopathy (BSE), and chronic
wasting disease (CWD), which are transmitted by
infection, usually exhibit deposition of PrP in plaques.
Interestingly, some scrapie strains develop plaques in
mice, i.e., 87V, and variant Creutzfeld-Jakob disease
(vCJD), which has been associated with the ingestion of
contaminated beef, usually exhibits high levels of PrP
protein-containing-plaques [18] as do the human dis-
eases Kuru [20] and Gerstmann-Straussler-Scheinker
syndrome (GSS). On the other hand, in the most com-
mon form of prion disease in humans, sporadic CJD
(sCJD), only 5–10% of cases show plaques [6], and
fatal familial insomnia and sporadic fatal insomnia are
both devoid of plaques [2, 6].
Recently, there has been a great deal of interest in the
role of transition metals in oxidative stress and neuro-
degenerative disease [24, 26, 36]. Since there is a well-
described association between the PrP and copper, we
and others have speculated that metal interactions and
oxidative stress may, like in other neurodegenerative
disorders, be critical to prion diseases [1, 5, 33, 38, 39]. In
the current study, we examined metal deposition in sev-
eral categories of human prion diseases, sCJD, GSS and
vCJD (Table 1). In sCJD, redox metal deposition was
never associated with PrP deposition. Conversely, in GSS
and vCJD, metal deposition is invariably associated with
PrP deposits, even in the absence of amyloid-b deposi-
tion. The oxidized nucleic acid base, 8-hydroxyguanosine
(8OHG), previously found increased in sCJD [14], is also
increased in cortical neurons in GSS along with mito-
chondrial (mt) DNA deletions. Other reactive oxygen
species, lipid peroxidation, heme oxygenase-1 (HO-1)
induction, and glycation were not detected in sCJD and
were only weakly associated with PrP deposits in GSS.
These findings suggest a distinction in oxidative stress
and metal accumulation in prion conditions marked by
whether PrP deposition is a constant feature.
Materials and methods
Tissue samples
The cases used in this study are outlined in Table 1.
Tissue used included cases of GSS, Indiana 198 kindred
(n=4, ages 49–77 years) [3, 27], vCJD (n=3, ages 25, 28,
29 years) [18], sCJD (n=19, ages 36–80 years, including
a series of cases categorized by subtype) [9]. Tissue was
fixed in either formalin or the non-aldehyde fixatives,
Carnoy’s or methacarn, dehydrated, and embedded in
Table 1 Case information
(CJD Creutzfeld-Jakob disease,
GSS Gerstmann-Straussler-
Scheinker syndrome)
Age Duration Genotype Fixative
(years) (months)
Sporadic CJD 66 3 Carnoy
54 12 MV Carnoy
80 5 MV mixed Carnoy
63 3 Carnoy
66 2 Methacarn
55 2 Methacarn
56 4 Methacarn
52 4 Methacarn
61 5 MV mixed Carnoy
79 4 MM1 Carnoy
66 1.5 MV1 Formalin
70 2 MM1 Formalin
71 2 MM1 Formalin
62 3 Formalin
58 3.5 VV2 Formalin
67 3.5 VV1 Formalin
74 6 MV1 Formalin
36 18 VV2 Formalin
62 9 MV2 Formalin
Variant CJD 25 10 M/M Formalin
28 9 M/M Formalin
29 10 M/M Formalin
GSS 49 7.2 Indiana 198 Carnoy
60 161 Indiana 198 Formalin
77 106 Indiana 198 Formalin
63 109 Indiana 198 Formalin
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paraffin. Samples of cortex, hippocampus and cerebel-
lum were studied from cases of sCJD, cerebellum and
hippocampus were analyzed from the GSS cases, and
cortex and cerebellum were analyzed from vCJD.
Immunocytochemistry
Sections were cut at 6 lm and placed on coated slides.
Immunocytochemistry was performed using the peroxi-
dase anti-peroxidase technique with 3,3’-diaminobenzi-
dine as substrate. Microwave treatment in HCl was used
for localization of prion deposits with monoclonal
antibody 3F4 [19]. Other markers used included poly-
clonal antisera against HO-1 [35], hydroxynonenal
(HNE) pyrrole adducts [31]), and carboxymethyllysine
(CML) [4], and monoclonal markers against amyloid-b
(4G8, Senetek) [25], cytochrome oxidase 1 (COX-1,
Molecular Probes) [16], 8OHG (Trevigen) [14], and
antiserum to ferritin (Dako).
Redox metals
Sites of redox-active iron were detected by incubation in
7% potassium ferrocyanide in 3% HCl and followed by
detection with diaminobenzidine and H2O2 as cosub-
trates (modified Perl stain) [36].
mtDNA deletions
Some sections were used to detect the 5-kb deletion in
mtDNA by in situ hybridization [16].
Results
Gerstmann-Straussler-Scheinker syndrome
Two sites of oxidative damage, namely PrP plaque and
vacuolar, were noted in the cases studied, and these
varied according to disease condition. In GSS, a great
number of prion-positive deposits were found in the
cerebellum and hippocampal sections, many with a
central core. Striking is the finding of redox-active iron
in the majority of the cored prion deposits and, in some
cases, within the presumed glia cells surrounding the
accumulations. Ferritin is also found associated with
some of the PrP deposits, and more strikingly, glial cells
prominent in affected areas (Fig. 1). Hippocampal and
temporal cortical neurons showed high levels of neuro-
nal 8OHG and mtDNA accumulation (Fig. 2). Heme
oxygenase-1 and CML are present around PrP deposits
of GSS, although at low levels (not shown). Prion
deposits, however, did not display amyloid-b (4G8), but
the neurons did display increased phosphorylated tau [3,
10] (data not shown).
Fig. 1 In GSS cerebellum,
prion deposits marked by 3F4
(A) also contain high levels of
redox-active iron (B). Ferritin-
positive cells also accumulate
around the deposits (C). In
another GSS case, redox-active
iron is also present in cells
surrounding PrP deposits (D)
(GSS Gerstmann-Straussler-
Scheinker syndrome, PrP prion
protein). A–C are serial
sections; bar 100 lm
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Variant CJD
In all three cases of vCJD, large numbers of diffuse and
focal PrP-containing deposits were seen. The dense focal
deposits were positive for redox-active metals, yet lacked
amyloid-b (Fig. 3).
Sporadic CJD
Prion deposits in the different cases of sCJD varied
morphologically from containing widely dispersed small,
thread-like aggregates to having many large defined
deposits (plaques). In no case was the redox iron asso-
ciated with PrP deposits. Four (ages 55, 58, 66, 74 years)
out of the 25 sCJD cases studied also contained amy-
loid-b-positive plaques. These 4G8-positive structures
contained redox-active metals (Fig. 4).
A further distinction between the deposits of PrP in
sCJD and those of PrP in GSS or amyloid-b in AD was
the lack of HO-1 or lipid peroxidation markers such as
HNE or CML surrounding the deposits in any of the
cases studied, irrespective of fixative (data not shown).
In this respect, the results using the methacarn or Car-
noy’s fixatives, in addition to formalin, are of particular
interest since the former usually display oxidative
modifications with greater sensitivity [32].
Discussion
In this study, we found that in both young and old cases
of GSS, iron and its storage protein, ferritin, are heavily
deposited in both the PrP lesions and surrounding cells.
Ferritin has recently been shown to be prominently co-
transported with protease-resistant PrP [23]. Iron, while
always found associated with amyloid-b deposits in AD,
is also in PrP in GSS and vCJD, independent of con-
comitant amyloid-b deposition. PrP deposits in sCJD
cases, however, lack iron deposition, further distin-
guishing this disease from the inherited or infectious
forms. This could be due to the shorter disease duration,
or less dense, variable PrP accumulations found in
sCJD. In this study, metal deposition was only found in
association with PrPsc found in amyloid plaques, not
with the amorphous deposits typically found in human
disease. This implies that the metal deposition either
requires the ordered structure found in the plaque,
which is not present in the amorphous deposits, or that
both arise by processes distinct to iron deposition. Thus,
simply possessing a b-sheeted structure does not suffice
for metal association. Other markers, such as HO-1,
HNE and CML, were found to be slightly increased in
GSS and vCJD pathological structures, but were not
increased in any case of sCJD. In addition, the pattern
Fig. 2 In GSS in the temporal
cortical layers, adjacent to
hippocampus, 8OHG (A) is
elevated in pyramidal neurons
as is mtDNA (B) (8OHG
8-hydoxyguanosine). Bar 50 lm
Fig. 3 Adjacent serial sections (landmark vessel shown by asterisk) of cortex from a case of vCJD show many cored, dense prion deposits
labeled with 3F4 (A) contain iron (B), but lack amyloid-b (C). This profile was found in all three vCJD cases studied (vCJD variant
Creutzfeld-Jakob disease). Bar 100 lm
235
of PrP deposition varied, and this may be one reason
why the oxidative damage profile neither compares to
the levels found in AD-related lesions nor occurs with
regularity, suggesting it is not a prominent feature of
lesion formation. The same can also be said for extra-
cellular PrP deposition in sCJD, which occurs with such
wide variability among cases, that this feature cannot be
essential. Typically, sCJD patients live only months after
diagnosis, while GSS and AD both have a disease course
lasting many years, possibly suggesting that a protracted
disease course is important for protective responses,
such as amyloid-b and formation of PrP deposition as
plaques, to be induced.
Other neurodegenerative diseases associated with
protein amyloid plaques, most notably Alzheimer dis-
ease, are also associated with aberrant iron deposits [36].
Such metal ions are redox active [17, 32], and always
contribute to increased oxidative stress including lipid
peroxidation and HNE adduction [31]. These data,
together with the findings presented in this study
emphasize the parallels that can be drawn between
various neurodegenerative disorders that likely have
completely different etiological backdrops [5].
The profiles of oxidative damage and iron deposition
found in prion diseases suggests parallels with AD. Early
markers of neuronal dysfunction, well characterized in
pyramidal neurons in AD, have also been localized in
CJD, namely, 8OHG. The pattern of localization was
varied, some cases exhibiting global neuronal accumu-
lations, while other cases showed small clusters of
positive cells [13]. This pattern was similar to the dense
accumulations of apoptotic neurons found in CJD [8].
However, in contrast, 8OHG was found increased to the
same extent in pyramidal neurons of the same anatomic
area in cases of AD.
PrP has been implicated in maintaining oxidant de-
fenses within cells [30, 39]. Increased PrP expression has
been shown to be closely followed by increased antioxi-
dant enzyme and glutathione levels in a cell culture
model [29]. Expanding these studies to a scrapie-infected
mouse model, it was further noted that PrPsc had a re-
duced copper-binding capacity, with a proportional de-
crease in cellular antioxidant levels [37]. Supporting the
role of metals in prion disease is the observation that
copper chelation delays the onset of prion disease in mice
inoculated by an intraperitoneal route [34].
Our findings, combined with previous studies impli-
cate oxidative stress as an important feature of prion
diseases, and further suggests that there are important
subtypes of oxidative responses in neurodegenerative
diseases.
Neuronal loss, additionally, is a ubiquitous feature of
both AD and CJD. In AD neuronal loss is highly cor-
related with dementia. All cases of CJD show demon-
strable neuron loss at levels of 45–60% in many areas of
the cortex [12]. However, the more striking feature of
Fig. 4 Cortical sections from a patient with sCJD with PrP deposits (age 66 years) (stained with 3F4, A) with concomitant amyloid-b
deposition (4G8, B). Redox-active metals (C) colocalize with only the amyloid-b deposits. Another patient with sCJD (age 36 years),
demonstrating aggregates of prion (3F4, D), contains neither amyloid-b (E), nor redox-active metals (F). A–C and D–F are adjacent serial
cortical sections with landmark vessels (arrows) (sCJD sporadic CJD). Bar 100 lm
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CJD is the spongiform change that results from vacuo-
lation in a large percentage of neurons. These neurons
would be expected to have impaired function. Consistent
with altered metabolism, increased levels of nitrotyro-
sine and heme-oxygenase in murine studies [13], nucleic
acid oxidation [14], and DNA fragmentation [8, 22] were
found in CJD.
It may be that b-pleated protein structures coordinate
the retention of free redox-active iron, and that loose
fibrillar and thread-like prion deposits in sCJD cases
may not exhibit the protein structures suitable for iron
deposition. The finding of iron deposits in vCJD, with
durations similar to sCJD, suggests that it is not simply
the duration of disease as might be implied by GSS or
iron deposits.
It has been suggested that metal imbalances,
resulting from oxidative stress, could be the initiating
factor responsible for altering the copper-binding
capacity of PrP, which in turn further drives oxidation
fluctuations and accumulation of PrPsc. In scrapie-in-
fected neuroblastoma cells, reduced iron metabolism
was found [7]. Hall and Edskes [15] have proposed a
two-hit model that drives prion disease development,
incorporating both the change in protein form and a
change in host state in the initiation and progression of
disease. This is reflective of an earlier proposal of a
two-hit model for AD [41, 42], where it was proposed
that both oxidative stress and mitotic signaling path-
ways are necessary for disease progression. Indepen-
dently, each factor could initiate disease state; however,
it is the combination with an altered cellular environ-
ment that propagates disease. Amyloids, including
normal PrP, may not retain their neuroprotective
functions when their protein form is changed. There-
fore, altered conformation combined with an oxida-
tively challenged environment results in neuronal loss
and apoptosis, i.e., neurodegeneration.
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